NEOS Investment Management LLC Acquires 2,887 Shares of ResMed Inc. $RMD

Posted by Stanley Muller on Sep 7th, 2026

NEOS Investment Management LLC boosted its holdings in ResMed Inc. (NYSE:RMD – Free Report) by 13.9% during the 2nd quarter, Holdings Channel reports. The firm owned 23,606 shares of the medical equipment provider’s stock after acquiring an additional 2,887 shares during the period. NEOS Investment Management LLC’s holdings in ResMed were worth $4,600,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of RMD. American Capital Management Inc. purchased a new stake in shares of ResMed during the 2nd quarter worth approximately $44,522,000. Hsbc Holdings PLC increased its position in ResMed by 17.6% in the fourth quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider’s stock worth $79,321,000 after buying an additional 49,253 shares during the last quarter. BlackRock Inc. bought a new stake in shares of ResMed in the second quarter valued at $2,400,375,000. Goldman Sachs Group Inc. raised its stake in shares of ResMed by 13.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider’s stock valued at $235,833,000 after buying an additional 118,296 shares during the period. Finally, Polymer Capital Management HK LTD purchased a new position in shares of ResMed during the 2nd quarter valued at $972,000. Institutional investors own 54.98% of the company’s stock.

Insider Transactions at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $205.69, for a total value of $1,026,598.79. Following the completion of the transaction, the chief executive officer directly owned 466,256 shares of the company’s stock, valued at $95,904,196.64. This trade represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 970 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total transaction of $227,688.10. Following the transaction, the director owned 51,803 shares of the company’s stock, valued at $12,159,718.19. This trade represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 18,952 shares of company stock worth $4,145,070. Insiders own 0.65% of the company’s stock.

ResMed Price Performance

Shares of NYSE RMD opened at $228.25 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. ResMed Inc. has a fifty-two week low of $180.26 and a fifty-two week high of $284.87. The stock has a market cap of $32.93 billion, a PE ratio of 21.88, a price-to-earnings-growth ratio of 1.44 and a beta of 0.77. The stock has a fifty day moving average of $215.51 and a 200-day moving average of $217.98.

ResMed (NYSE:RMD – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.89 by $0.06. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.46 billion. ResMed had a return on equity of 25.58% and a net margin of 26.94%.The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.55 EPS. Equities research analysts anticipate that ResMed Inc. will post 12.02 earnings per share for the current year.

ResMed Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 24th. Stockholders of record on Thursday, August 20th will be issued a $0.66 dividend. The ex-dividend date of this dividend is Thursday, August 20th. This is a positive change from ResMed’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s payout ratio is currently 25.31%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RMD shares. Wells Fargo & Company cut their price target on ResMed from $225.00 to $215.00 and set an “equal weight” rating for the company in a research note on Friday, August 7th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ResMed in a report on Wednesday, July 1st. Citigroup reiterated a “neutral” rating and set a $235.00 target price (down from $270.00) on shares of ResMed in a research report on Sunday, July 12th. Morgan Stanley reiterated an “equal weight” rating and issued a $230.00 target price (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Finally, Weiss Ratings raised shares of ResMed from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $240.31.

Check Out Our Latest Stock Analysis on RMD

About ResMed

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.